Colour vision defects in schizophrenia spectrum disorders: A systematic review
- PMID: 40656100
- PMCID: PMC12244155
- DOI: 10.1016/j.nsa.2024.104046
Colour vision defects in schizophrenia spectrum disorders: A systematic review
Abstract
This systematic review synthesized the existing literature to summarize colour vision disturbances experienced by patients with schizophrenia. A comprehensive literature search compliant with PRISMA-2020 was conducted in Medline and Embase from inception to February 28, 2023. Studies were included if they: (1) included people diagnosed with schizophrenia, (2) investigated colour vision, (3) had a comparator with or without schizophrenia. Study quality appraisal was performed using the NIH Study Quality Assessment Tool. Seven studies of fair quality with 695 patients were included, of whom, 46.5% (n = 323) patients were diagnosed with a schizophrenia-spectrum disorder. Compared to healthy controls, patients with schizophrenia either made more mistakes in discriminating between colours, or were delayed in recognizing colours. One study found that Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scores correlated weakly with error scores related to colour vision impairments. The most common shortcomings were lack of sample size justification (k = 7, 100%), and lack of blinding (k = 7, 100%). Our review indicates early evidence of colour vision deficits among patients with schizophrenia, and an unclear relationship between severity of schizophrenia with colour vision deficits. Possible mechanisms may include alterations in retinal dopamine transmission or schizophrenia-related cognitive deficits interacting with colour vision outcomes. Future studies may benefit from large registry analyses of patients with various schizophrenia spectrum disorders, analyzing ocular parameters (e.g., OCT), collecting data on cognitive impairment, and pursuing multivariate analyses to elucidate mechanisms for schizophrenia-related colour vision changes.
Keywords: Colour blindness; Colour vision; Schizophrenia.
© 2024 Published by Elsevier B.V. on behalf of European College of Neuropsychopharmacology.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD013100. doi: 10.1002/14651858.CD013100.pub2. Cochrane Database Syst Rev. 2022. PMID: 35844143 Free PMC article.
-
Selective noradrenaline reuptake inhibitors for schizophrenia.Cochrane Database Syst Rev. 2018 Jan 25;1(1):CD010219. doi: 10.1002/14651858.CD010219.pub2. Cochrane Database Syst Rev. 2018. PMID: 29368813 Free PMC article.
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Colour vision impairments in bipolar disorder: A systematic review.Neurosci Appl. 2024 Mar 15;3:104057. doi: 10.1016/j.nsa.2024.104057. eCollection 2024. Neurosci Appl. 2024. PMID: 40656079 Free PMC article. Review.
-
Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults.Cochrane Database Syst Rev. 2023 Aug 18;8(8):CD013244. doi: 10.1002/14651858.CD013244.pub2. Cochrane Database Syst Rev. 2023. PMID: 37593770 Free PMC article.
References
-
- Barbur J., Wong S. Colour vision changes in patients with pressure differences across the lamina cribrosa. Acta Ophthalmol. 2022;100 doi: 10.1111/j.1755-3768.2022.15367. j.1755-3768.2022.15367. - DOI
-
- Brébion G., Stephan-Otto C., Usall J., Huerta-Ramos E., Perez Del Olmo M., Cuevas-Esteban J., Haro J.M., Ochoa S. Association of auditory-verbal and visual hallucinations with impaired and improved recognition of colored pictures. Neuropsychology. 2015;29:667–674. doi: 10.1037/neu0000169. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources